The FDA has approved nivolumab, in combination with certain chemotherapies, for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal…
The FDA granted accelerated approval to sacituzumab govitecan to treat adult patients with locally advanced or metastatic urothelial cancer (mUC), who have previously received a platinum-containing…
WGS could be an alternative to conventional cytogenetic analysis in patients with AML or MDS, according to Eric J. Duncavage, MD, et al.
Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.
Long-term follow-up from the FoRT study shows that the optimal RT dose for patients with indolent NHL and histologic FL or MZL is 24 Gy in 12 fractions.
The FDA has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
The FDA has approved a higher dose of cetuximab for the treatmen of patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck.
The FDA has approved isatuximab-irfc plus carfilzomib and dexamethasone for the treatment of adults with relapsed/refractory MM given 1 to 3 previous lines of therapy.
Advanced stage NSCLC 80 years and older saw improvement in overall survival when treated with chemotherapy.
Post-operative systemic chemo and RT did not improve OS in high-risk patients with stage I endometrial cancer, according to Rachelle Findley, MD, et al.
Stay in the know.
OncNet Newsletter